Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
SUSPENDED
PHASE2
20 participants
INTERVENTIONAL
2018-12-05
2023-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Oral Versus Vaginal Progesterone for Luteal Phase Supplementation in Frozen Embryo Transfer Cycles
NCT04758871
HRT Versus MOS for Endometrial Preparation Prior to FET in Non PCOS Patients
NCT02330757
Ovarian Hyperstimulation Syndrome Prevention
NCT06739759
Cabergoline Versus GnRH Antagonist Rescue and Cabergoline in the Prevention of Ovarian Hyperstimulation Syndrome
NCT02461875
Micronized Progesterone vs Gonadotropin-releasing Hormone (GnRH) Antagonist in Freeze-all IVF Cycles.
NCT04108039
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
control
dydrgesterone 10 mg( tab)/12hs/14 days
dydrgesterone 10 mg( tab)/12hs/14 days
Dydrogesterone Oral Tablet 10 mg twice daily for 14 days to be taken from the day of ovum pickup
study
montelukast 10 mg(tab) oral/24hs/ 7 days dydrgesterone 10 mg( tab) oral/12hs/14 days
montelukast 10 mg(tab) oral/24hs/ 7 days dydrgesterone 10 mg( tab) oral/12hs/14 days
montelukast 10 mg(tab) once daily oral for 7 days \& dydrgesterone 10 mg (tab) twice daily oral for 14 days \&
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
dydrgesterone 10 mg( tab)/12hs/14 days
Dydrogesterone Oral Tablet 10 mg twice daily for 14 days to be taken from the day of ovum pickup
montelukast 10 mg(tab) oral/24hs/ 7 days dydrgesterone 10 mg( tab) oral/12hs/14 days
montelukast 10 mg(tab) once daily oral for 7 days \& dydrgesterone 10 mg (tab) twice daily oral for 14 days \&
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
20 Years
37 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hawaa Fertility Center
OTHER
Benha University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ahmed Saad
Assistant professor of Ob. & Gyn.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
ahmed sa saad, MD, ph D
Role: PRINCIPAL_INVESTIGATOR
Hawaa Fertility Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Banha University- Hawaa Fertility center
Banhā, Qalyubia Governorate, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Hawaa-5
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.